Please assess the completion status of the following clinical trial:

Trial Title: Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Chinese males~* aged ≥ 18 and ≤ 45~* body mass index (BMI) ≥ 19 and ≤ 26 kg/m2~* LVEF≥ 55%~Exclusion Criteria:~* A history of any serious clinical disease such as haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, mental, neurological diseases, and tumour, or allergic diseases~* Use of a monoclonal antibody or any biological product within 6 months before study drug administration~* A history of allergic reactions or anaphylaxis, including such reactions to any drug or excipient in the clinical study~* Use of prescription drugs, over-the-counter drugs (OTC), or traditional Chinese medicine (TCM) (excluding vitamins, mineral supplements, and dietary supplements) within 28 days before study drug administration~* A history of blood donation within 3 months before study drug administration~* Participation in other clinical study and use of the investigational product/comparator within 3 months before study drug administration~* Positive for hepatitis B surface antigen (HbsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, or treponema pallidum antibody~* A history of drug abuse~* Failure to comply with protocol requirements, instructions, and study limitations, such as uncooperative attitude, failure to return to the study site for follow-up visits, or failure to complete the entire clinical study, as judged by investigators

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- HLX11 group (Type: EXPERIMENTAL): HLX11 are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
- CN-Perjeta group (Type: ACTIVE_COMPARATOR): CN-Perjeta are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
- EU-Perjeta group (Type: ACTIVE_COMPARATOR): EU-Perjeta are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
- US-Perjeta group (Type: ACTIVE_COMPARATOR): US-Perjeta are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).

Based on this trial design, predict the completion outcome and termination type (if applicable).